It is verified that the overexpression of HER2 protein is related to tumor progression and poor prognosis in bladder cancer, and the efficacy of cisplatin-based NAC in HER2-positive urothelial bladder cancer is unsatisfactory (12–14). The gene discussed is ERBB2; the disease is bladder transitional cell carcinoma.